

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61M 25/10</b>	<b>A1</b>	(11) International Publication Number: <b>WO 95/18646</b> (43) International Publication Date: 13 July 1995 (13.07.95)
--	-----------	---

(21) International Application Number: PCT/US95/00082

(22) International Filing Date: 3 January 1995 (03.01.95)

(30) Priority Data:  
08/177,332 4 January 1994 (04.01.94) US

(71) Applicant: CORTBAK MEDICAL, INC. [US/US]; 2660 Patton Road, Roseville, MN 55113 (US).

(72) Inventor: HILDEBRAND, Keith, R.; 422 Highland View, Houston, WI 54082 (US).


(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter &amp; Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).

Published

With international search report.

(54) Title: PROSTATIC DRUG-DELIVERY CATHETER



## (57) Abstract

A method and apparatus for the treatment of a prostate gland which isolates the prostatic urethra from the membranous urethra and the bladder so that fluid may be transported into the prostatic ducts without compromising the openings to the prostatic ducts. One preferred embodiment incorporates balloons located at either end of the prostatic urethra to isolate the same.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TE	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

PROSTATIC DRUG-DELIVERY CATHETERTechnical Field

The present invention relates to a catheter for the treatment of a prostate gland, and more specifically to a catheter that isolates the prostatic urethra from the membranous urethra and the bladder so that fluid may be transported into the prostatic ducts without compromising the openings to the prostatic ducts.

10

Background

Many techniques exist for delivering drugs or other medicaments to body tissue. These techniques include oral administration; injection directly into body tissue, such as through an intramuscular injection; topical or transcutaneous administration where the drug is passively absorbed into, or caused to pass across, the skin or other surface tissue; and intravenous administration, which involves introducing a selected drug directly into the blood stream.

Except for topical or transcutaneous administration, the above drug delivery systems tend to be systemic. In other words, administration of the drug is delivered throughout the body by the blood stream. Transcutaneous drug delivery systems deliver a drug locally to a selected area, and are limited to external application of a drug through the patient's skin or other surface tissue. Thus, the above described drug delivery systems generally are not appropriate for the localized treatment of internal body tissue.

Although many medical situations are satisfactorily treated by the general systemic administration of a drug, there are many treatments that are facilitated and/or improved by the ability to deliver or administer a drug locally to a selected portion of internal body tissue, without appreciably affecting the surrounding tissue. One example is the prostate gland, which is subject to various diseases such as prostatitis, benign prostatic hyperplasia, and prostate cancer. The urethra

allows relatively easy access to the prostate from outside the patient by means of a catheter.

The urethra includes the prostatic urethra and the membranous urethra. All of the major ducts of the prostate gland open on the surface of the prostatic urethra. These ducts extend into the prostate and branch into ductules (smaller ducts) and eventually end in acini (rounded sacs). The outside of the prostate gland is surrounded by a tough fibrous capsule that serves as a substantial physical barrier between the spongy prostatic tissue and the rest of the peritoneal environment. By using an appropriately designed catheter that is introduced through the urethra, it is possible to access the prostate via the prostatic ducts that extend deep into the gland.

Two previous patents have disclosed catheters for delivering drugs to tissue to the prostate gland via the prostatic urethra and the prostatic ducts. United States Patent Nos. 5,007,897 and 4,423,725 disclose catheters having drug-delivery bladders made from a porous membrane. These patents teach placing the drug-delivery balloon into the prostatic urethra and inflating the balloon with a drug in a fluid form. The drug is pressurized so that it is caused to pass through the porous or perforated membrane and transported into the prostatic ducts.

There is a significant problem that results from delivering the drug through this type of membranous balloon. Specifically, the transport of the drug into the prostate gland is impeded and thus much less efficient.

There are two impediments. The first impediment is that the pressurized balloon expands and exerts a force against the walls of the prostatic urethra. This force compresses the prostatic tissue and causes the ducts to restrict and block the flow of the drug into the prostate gland. As a result, the drug typically does

of a balloon in the prostatic urethra also means that there is no membrane interface between the drug and prostate gland to restrict the flow of the drug into the prostatic ducts.

5       The present invention delivers fluid to the prostatic urethra in the gap formed between the occlusion balloons. The fluid can then be pressurized so that it will transport through the prostatic ducts. Unlike current designs, the present invention allows for  
10 two independent inflation pressures. One pressure is for the occlusion balloons and the other pressure is for drug delivery. The ability to control the two pressures independently allows the operator to apply a higher pressure to the occlusion balloons than the pressure for  
15 the drug delivery. Thus, the operator can maximize the drug delivery pressure without having to be concerned that a significant amount of the drug can leak around the occlusion balloon and into the bladder or membranous urethra.

20       There is further advantage in the present invention in that a drug in a fluid form or a diagnostic fluid can be more evenly distributed throughout the prostate gland. Additionally, the drug or diagnostic fluid can be delivered quicker, thereby resulting in a shorter  
25 administrative time. The shorter administration time will also result in reduced medical expenses.

      An additional advantage of the present invention is that the drug or diagnostic fluid is prevented from leaking into the membranous urethra or the bladder. The  
30 result is that a much higher percentage of the delivered fluid is transported into the prostate gland. Therefore, the fluid is conserved and waste is kept to a minimum.

      One embodiment of the present invention comprises a  
35 catheter having distal and proximal ends, a drainage lumen, a plurality of inflation lumens, and a delivery lumen. A positioning balloon is operably connected to

not distribute evenly throughout the ducts, nor throughout the prostate gland. Compression of the prostatic ducts also prevents or slows the flow of the drug solution into the interior of the prostate gland.

5       The second impediment is the porous membrane through which the drug solution must pass before it enters the prostatic ducts. Such an impediment slows the flow of the drug solution and results in additional inefficiency.

10       Slowing the flow of the drug solution results in longer delivery times and most likely lower levels of drug in the prostate gland. Additionally, a longer administration period requires additional time from the medical personnel. This expense is passed on to the  
15 patient, thereby increasing the cost of treatment.

          Therefore, there is a need for a catheter that is capable of delivering drugs and diagnostic fluids to the prostate gland via the prostatic urethra and prostatic ducts, wherein the catheter does not compromise flow  
20 through the prostatic ducts by exerting pressure against the walls of the prostatic urethra.

#### Summary

          The present invention provides a catheter for  
25 treating the prostate gland which isolates the prostatic urethra from the membranous urethra and the bladder so that fluid may be transported into the prostatic ducts without compromising flow through the openings to the prostatic ducts and without substantial leakage of the  
30 fluid out of the prostatic urethra.

          One preferred embodiment of the present invention comprises a catheter having two occlusion balloons separated by a distance that is approximately the same length as the prostatic urethra. Thus, no balloon  
35 exerts pressure against a significant portion of the prostatic urethra to cause a restriction of a significant portion of the prostatic ducts. The absence

the distal end of the catheter and an inflation lumen is capable of passing fluid to the interior of the positioning balloon.

A proximal occlusion balloon is operably connected to the catheter and an inflation lumen is capable of passing fluid to the interior of the proximal occlusion balloon. A distal occlusion balloon is situated between the positioning balloon and the proximal occlusion balloon and operably connected to the catheter. A delivery lumen is capable of delivering a fluid to the interior of the distal occlusion balloon.

Additionally, the distal occlusion balloon is capable of isolating substantially all of the prostatic urethra from substantially all of the membranous urethra and the proximal occlusion balloon is capable of providing minimal leakage of fluid in the bladder. A delivery lumen is capable of passing fluid to the gap between the distal and proximal occlusion balloons. Pressurizing the fluid in the gap will cause it to be transported through the prostatic ducts.

In one preferred embodiment of the present invention, the proximal occlusion balloon and the distal occlusion balloon are separated by approximately 3 centimeters to approximately 6 centimeters.

The distance between the proximal and distal occlusion balloons is adjustable in an alternative preferred embodiment of the present invention. In the adjustable embodiment, the catheter comprises first and second parts wherein the distal occlusion balloon is operably connected to the first part and the proximal occlusion balloon is operably connected to the second part. The first part is slidably connected to the second part so that the distance between the distal and proximal occlusion balloons is adjustable.

One preferred embodiment of the present invention also comprises syringe-type pumps in fluid communication with the delivery lumens for injecting fluid into the

gap between the proximal and distal occlusion balloons and pressurizing the fluid so that it is forced to transport into the prostatic ducts.

Still further embodiments comprise phonophoresis, 5 iontophoresis, and/or electroporation capabilities to assist the transport of the drug into the prostatic ducts and into the prostatic tissue. A still further embodiment comprises a heating element positioned between the first and second occlusion balloons to heat 10 the fluid and the prostatic tissue as it transports from the prostatic urethra into the prostatic ducts.

These and other advantages and features, which characterize the present invention, are pointed out with particularity in the claims annexed hereto and forming a 15 further part hereto. For a better understanding of the invention, however, reference should be made to the drawings, which form a further part hereto and to the detailed description, which describes a preferred embodiment of the present invention.

20

#### Description of the Drawings

Figure 1 is a view in partial cross-section of the catheter of the present invention located in the drug delivery position within the male urethra and bladder.

25 Figure 2 is an enlarged cross-sectional view of the catheter of Figure 1.

Figure 3 is a partial view in partial cross-section of an alternative embodiment of a catheter according to the present invention, in which the positioning balloon 30 and the distal occlusion balloon are combined into a unitary balloon.

Figure 4 is a cross-sectional view of one alternative embodiment of a catheter according to the present invention in which the catheter body is 35 telescoping.

Figure 4A is a cross-sectional view along the longitudinal axis of the catheter of Figure 4, taken



along Line 4A-4A.

Figure 4B is a cross-sectional view along the longitudinal axis of another alternative embodiment of a telescoping catheter according to the present invention.

5        Figure 5 is a partial view of an alternative embodiment of a catheter according to the present invention that includes a coil-wired electrode.

Figure 6 is a partial cross-section of the catheter of Figure 5 and further shows the coil-wired electrode  
10        connected to a power source and a patch-type electrode.

Figure 7 is a partial view of an alternative embodiment of a catheter according to the present invention including first and second ring-type electrodes.

15        Figure 8 is a partial cross-sectional view of the catheter of Figure 7 and further shows the first and second ring-type electrode connected to a power source.

Figure 9 shows an alternative embodiment of a catheter according to the present invention further  
20        comprising a transducer.

Figure 10 is a partial cross-sectional view of the catheter of Figure 9 and further shows the transducer connected to a power source.

Figure 11 is a partial cross-sectional view of an  
25        alternative embodiment of a catheter according to the present invention comprising a coil-type resistor connected to a power source.

#### Detailed Description

30        One preferred embodiment of the invention will be described in detail with reference to the drawings, wherein like reference numerals represent like parts and assemblies throughout the several views. Reference to the preferred embodiment does not limit the scope of the  
35        invention, which is limited only by the scope of the claims attached hereto.

The present invention comprises a catheter with two

balloons for isolating a target area for treatment. The catheter is capable of delivering fluid to the target area of the passageway that is isolated between the balloons. The present invention can be used to deliver  
5 fluid to the prostate gland and is advantageous in that the prostatic ducts remain substantially open, even when the balloons are inflated.

A catheter including two occlusion balloons is disclosed in commonly-assigned United States Patent  
10 Application Serial Nos. 07/705,731, filed on May 24, 1991 and 07/937,464 filed on August 28, 1992, both of which are incorporated by reference for the purpose of providing teachings regarding catheters that incorporate a plurality of occlusion balloons.

15 Referring now to Figures 1 and 2 which illustrate one preferred embodiment of a catheter according to the present invention, generally shown as 20, for isolating and treating a prostate gland. Catheter 20 has a catheter body 22 that includes a distal end 24 and a  
20 proximal end 26. Positioning balloon 28 is affixed to distal end 24 of catheter body 22 such that catheter body 22 passes through positioning balloon 28 and positioning balloon 28 is sealed to catheter body 22. Distal occlusion balloon 30 is affixed to catheter body  
25 22 in a fashion similar to the method by which positioning balloon 28 is affixed. Distal occlusion balloon 30 is positioned on catheter body 22 such that distal occlusion balloon 30 will sit in the neck 54 of the bladder 46 when catheter 20 is located in its drug  
30 delivery position. Locating catheter 20 in the drug delivery position will be described in more detail below.

Proximal occlusion balloon 34 is affixed to catheter body 22 in a manner similar to distal occlusion  
35 balloon 30 and positioning balloon 28. The distance between distal occlusion balloon 30 and proximal occlusion balloon 34 is approximately the same length as

the average prostatic urethra 90. Thus, distal occlusion balloon 30 and proximal occlusion balloon 34 isolate substantially all of the prostatic urethra 90 from substantially all of the membranous urethra 36 and substantially all of the bladder neck 54. Furthermore, proximal occlusion balloon 34 and distal occlusion balloon 30 are spaced far enough apart so that the balloons 30 or 34 exert minimal pressure against the wall of the prostatic urethra 90. Thus, a minimal number of prostatic ducts are caused to collapse when catheter 20 is in the drug delivery position, as described below. Preferably, the distance between distal occlusion balloon 30 and proximal occlusion balloon 34 is in the range from approximately 3 centimeters to approximately 6 centimeters. In order to accommodate prostatic urethras 90 of different lengths, medical personnel may have several catheters 20 available, each having different distances between the distal occlusion balloon 30 and proximal occlusion balloon 34.

Preferably, positioning balloon 28 has a diameter in the range of approximately 2 centimeters to approximately 4 centimeters when inflated. The most preferred diameter of positioning balloon 28 when inflated is 2.5 centimeters. Balloons 28, 30, and 34 can be made from either elastic material or inelastic material. Examples of suitable elastic materials include latex, polyurethane, or silicon. Examples of suitable inelastic materials include polyethylene, polycarbonate, or PET. However, the preferred material is polyurethane.

Catheter body 22 includes 4 lumens: drainage lumen 38, first inflation lumen 40, second inflation lumen 42, and delivery lumen 44. Drainage lumen 38 extends from distal tip 60 of catheter body 22 to proximal end 26. As described in more detail below, drainage lumen 38 drains urine from the bladder 46 when the catheter 20 is

inserted into the urethra 48.

First inflation lumen 40 extends from the proximal end 26 to a position proximate the positioning balloon 28. First inflation port 50 passes from first inflation lumen 40 to the interior of positioning balloon 28 so that positioning balloon 28 can be inflated by injecting a fluid through first inflation lumen 40.

Second inflation lumen 42 extends from a position proximate proximal end 26 of catheter body 22, past proximal occlusion balloon 34, to a position proximate distal occlusion balloon 30. Second inflation port 52 passes from second inflation lumen 42 into the interior of distal occlusion balloon 30. Similarly, third inflation port 56 passes from second inflation lumen 42 to the interior of proximal occlusion balloon 34. Therefore, distal occlusion balloon 30 and proximal occlusion balloon 34 can be inflated simultaneously by injecting a fluid into second inflation lumen 42. One skilled in the art will appreciate that a third inflation lumen could be added to catheter body 22 so that distal occlusion balloon 30 and proximal occlusion balloon 34 could be independently inflated.

Delivery lumen 44 extends from a position proximate proximal end 26 of catheter body 22 to a position proximate the gap between distal occlusion balloon 30 and proximal occlusion balloon 34. Delivery ports 56 pass from delivery lumen 44 to the outer surface 58 of catheter body 22. Catheter body 22 may define as many as 20 delivery ports 56, which are macroscopic in size. Preferably, there are three or four delivery ports 56. The size of the delivery ports is preferably in the range from approximately 1 millimeter to approximately 2 millimeters. The most preferred size for the delivery ports is 1 millimeter.

The procedure for using catheter 20 is as follows. Catheter 20 is inserted into the urethra 48 using lubrication, sterile techniques, and any other technique

that is commonly used to insert a Foley-type urological catheter. Catheter 20 is inserted into the urethra 48 until positioning balloon 28 enters the bladder 46 and is preferably inserted while there is urine within the bladder 46. Having urine within the bladder 46 is useful because the medical person who inserts catheter 20 will know that positioning balloon 28 has entered the bladder 46 when urine is observed in drainage lumen 38 or when urine can be aspirated through drainage lumen 38.

Once positioning balloon 28 is inserted within the bladder 46, fluid is injected through first inflation lumen 40 until positioning balloon 28 is inflated to a diameter of approximately 2 centimeters to approximately 4 centimeters. A predetermined, fixed volume of fluid is preferably used in order to prevent over inflation and bursting of positioning balloon 28. The fluid can be air, water, or saline, etc. However, the preferable fluid is sterile water.

After positioning balloon 28 is inflated, retrograde tension is applied to catheter 20 by pulling on the exposed portion of catheter body 22. This action seats positioning balloon 28 against the junction 53 between the bladder 46 and the neck 54 of the bladder 46. Retrograde tension is maintained by taping the exposed catheter body 22 to the patient's body. Catheter 20 is in the drug delivery position when positioning balloon 28 is seated against the junction 53 between the neck 54 and the bladder 46.

When in the drug delivery position, distal occlusion balloon 30 is positioned so that it is primarily located in the bladder neck 54. However, a portion of distal occlusion balloon 30 may be located within the portion 91 of the prostatic urethra 90 closest to the neck of the bladder. The reason is that substantially all of the prostatic ducts open in the portion 89 of the prostatic urethra. Consequently,

positioning distal occlusion balloon 30 in this manner causes a minimal amount, if any, of the prostatic ducts to seal shut when catheter 20 is in the drug delivery position. Additionally, proximal occlusion balloon 34 is located within the membranous urethra 36 and adjacent to, but not substantially within, the prostatic urethra 90.

After catheter 20 is located in the drug delivery position, distal occlusion balloon 30 and proximal occlusion balloon 34 are inflated by injecting a fluid into second inflation lumen 42. A predetermined, fixed volume of fluid is preferably used in order to prevent over inflation and bursting of distal and proximal occlusion balloons 30 and 34. The fluid can be air, water, or saline, etc. However, the preferred fluid is sterile water.

Drugs or diagnostic fluids may be delivered to the prostate gland 92 after catheter 20 is in the drug delivery position and positioning balloon 28, distal occlusion balloon 30, and proximal occlusion balloon 34 are inflated. One skilled in the art will realize that a pressure gauge and syringe can be placed in fluid communication with delivery lumen 44 to deliver the drug or diagnostic fluid to the prostatic urethra 90. Any number of types of syringes may be used such as a standard syringe, an adjustable syringe, or a syringe pump. However, an adjustable syringe is preferably used. An adjustable syringe is one that has threads or some other type of self-locking mechanism.

Once delivered, the drug or diagnostic fluid is pressurized, thereby transporting it into the ducts, ductules, and acini. The pressure on the fluid may range between from approximately 0.1 psi to approximately 10 psi. However, the preferable pressure is between approximately 1 psi and approximately 6 psi. The most preferred range of pressure is between approximately 2 psi and approximately 5 psi. This

pressure causes the fluid to fill the prostatic ducts, ductules, and acini.

Preferably, a constant pressure should be maintained over a period of time ranging from approximately 0.25 hours to approximately 4 hours. The preferred range of time is between approximately 0.25 hours to approximately 2 hours, and the most preferred range is between approximately 0.25 hours and approximately 0.5 hours. One skilled in the art will realize that the precise amount of time will vary depending on the drug or the diagnostic agent being employed.

Maintaining constant pressure over a period of time, rather than a simple administration of a fixed volume of drug solution, will more likely result in homogeneous prostatic tissue concentrations. If accurate drug dosing is not required, a fixed volume of solution can be simply administered. An example of when a fixed volume of solution is appropriate is when a positive contrast agent is introduced into the prostate gland 92.

The preferable procedure for withdrawing catheter 20 from the urethra 48 depends on whether toxic or caustic agents were delivered. For nontoxic drugs and diagnostic fluids such as antibiotics, anti-inflammatories, positive contrast agents, etc., the pressure of the fluid is simply reduced to zero, positioning and occlusion balloons 28, 30, and 34 are deflated, and catheter 20 is removed from the urethra 48.

If toxic or caustic agents were delivered, an alternative procedure for withdrawing catheter 20 is preferred. More specifically, a slight negative pressure is applied to the fluid in order to remove the excess drug or diagnostic agent from the prostatic urethra 90 after the administration period is complete. The prostatic urethra 90 may then be flushed with a

saline solution. The saline solution is added and removed via delivery lumen 44 in the same fashion the drug or diagnostic fluid was initially delivered to the prostatic urethra 90. After the saline solution is removed, positioning and occlusion balloons 28, 30, and 34 are deflated and catheter 20 is removed.

Figure 3 illustrates a first alternative embodiment in which a pear-shaped balloon 62 serves as a unitary positioning balloon and distal occlusion balloon. More specifically, pear-shaped balloon 62 has a narrow portion 64 for isolating the prostatic urethra 90 and a wide portion 66 for locating catheter 20 in the drug delivery position. One skilled in the art will realize that catheter body 22 may have either a common inflation lumen for both proximal occlusion balloon 34 and pear-shaped balloon 62, or have separate delivery lumens for these balloons 34 and 62. One skilled in the art will further realize that this alternative embodiment is used in a fashion similar to the embodiment described above.

Referring now to Figure 4, a further alternative embodiment comprises a telescoping catheter body 68 comprised of a tubular portion or part 70 and an extendable portion or part 72, which is inserted within and extends the entire length of tubular portion 70. Thus, extendable portion 72 slidably engages tubular portion 70. Tubular portion 70 includes an inner surface 82 within which tubular portion 72 slides.

In this embodiment, positioning balloon 28 and distal occlusion balloon 30 are attached to extendable portion 72 in a manner identical to that described above. Proximal occlusion balloon 34 is attached to tubular portion 70.

Extendable portion 72 defines a drainage lumen 38, first inflation lumen 40, first inflation port 50, second inflation lumen 42, and second inflation port 52. First inflation lumen 40 extends from a position proximate proximal end 94 of extendable portion 72 to a



position proximate positioning balloon 28. First inflation port 50 passes from first inflation lumen 40 to the interior of positioning balloon 28. Second inflation lumen 42 extends from a position proximate the proximal end 94 of catheter body 68 to a position proximate distal occlusion balloon 30. Second inflation port 52 passes from second inflation lumen 42 to the interior of distal occlusion balloon 30.

In the preferred embodiment, depicted in Figure 4A in a cross-sectional view taken along the longitudinal axis, there is a slight gap 85 between the extendable portion 72 and the tubular portion 70. During delivery and transport, the fluid passes through the gap 85 to the prostatic urethra. Tubular portion 70 defines a third inflation lumen 78 that extends from the proximal end 94 to a position proximate proximal occlusion balloon 34. Third inflation port 80 extends from a third inflation lumen 78 to the interior of proximal occlusion balloon 34.

An alternative embodiment of the telescoping catheter is shown in cross-section in Figure 4B. In this embodiment, a groove 84 extends along inner surface 82 of tubular portion 70. When extendable portion 72 is inserted within tubular portion 70, groove 84 and outside surface 86 of extendable portion 72 form a delivery lumen. Delivery lumen 88 extends along the length of tubular portion 70 so that end 96 of groove 84 opens at the end of tubular portion 70. Thus, delivery lumen 88 is in fluid communication with the gap between distal occlusion balloon 30 and proximal occlusion balloon 34.

One skilled in the art will realize that gap 85 and groove 84 could be replaced with a delivery lumen located in extendable portion 72. One skilled in the art will further realize that the delivery lumen could be alternatively placed in the tubular portion 70.

Use of this telescoping catheter is similar to the

use of the embodiment described above. The major difference is that the telescoping catheter allows the medical personnel to adjust the distance between the occlusion balloons 30 and 34 so that the distance  
5 between the occlusion balloons 30 and 34 matches the length of the particular patient's prostatic urethra 90.

Before using the telescoping catheter, medical personnel will assess the length of the prostatic urethra 90 by measuring the size of the prostate gland.  
10 The size of the gland can be measured through currently available methods including a digital rectal exam, transrectal ultrasound, CT scan, or MRI. Before inserting the catheter, the medical personnel should adjust the distance between the occlusion balloons to  
15 match the length of the prostatic urethra 90. Simple gradations on the exposed portion of the extendable portion 72 of the catheter body would allow the user to know the exact distance between the occlusion balloons 30 and 34.

20 Further alternative embodiments utilize iontophoresis, electroporation, and phonophoresis to assist the transportation of the fluid into the prostatic ducts. These non-pressure means of transportation also enhance drug penetration across the  
25 prostatic epithelium and into prostatic tissue. These methods may also increase cellular penetration of certain agents. Examples of these agents include DNA, RNA, etc. These non-pressure means of transportation may also make penetration into prostatic calculi  
30 possible.

Referring now to Figures 5 and 6, a catheter that utilizes iontophoresis has a coil-wired electrode 98 that circumscribes catheter body 22 in the gap that is formed between distal occlusion balloon 30 and proximal  
35 occlusion balloon 34. Referring to Figure 6, lead 100 passes through delivery lumen 44 and has one end attached to coil-wire electrode 100 and an opposite end

attached to power supply 102. Patch-type return electrode 104 is also attached to power supply 102 and is mountable on a person's body. Alternatively, the return electrode can be mounted internally or on the catheter body 22 remote from electrode 98.

In operation, catheter 20 is located in the drug delivery position as described above. Coil-wire electrode 98 will be located within the prostatic urethra 90 when catheter 20 is in the drug-delivery position. Patch-type electrode 104 is then mounted on the patient's skin so that the prostate gland 92 is located between electrodes 98 and 104. Using the methods described above, drugs or diagnostic fluids are delivered to the prostatic urethra 90 and then pressurized so that they can be transported into the prostatic ducts. The electrodes 98 and 104 are then activated, which assists the transport. United States Patent Application Serial Nos. 07/705,731 filed on May 24, 1991; 07/937,464 filed on August 28, 1992; and 07/957,209 filed on October 6, 1992 describe the use of iontophoresis in conjunction with catheters in greater detail and are incorporated by reference.

Referring to Figures 7 and 8, a catheter 20 which can be used for iontophoresis or electroporation has first and second ring-type electrodes 106 and 108 which circumscribe catheter body 22. First electrode 106 is proximate distal occlusion balloon 30 and second electrode 108 is proximate proximal occlusion balloon 34. Referring to Figure 8, one end of leads 100 and 110 are connected to electrodes 106 and 108, respectively and are fed through delivery lumen 44. The opposite ends of leads 100 and 110 are connected to power supply 102. A catheter 20 that includes electrodes 98 and 104 for electroporation is used in a similar fashion to a catheter 20 that includes electrodes 106 and 108 for iontophoresis. The primary difference is that there is not a patch-type electrode 104 that must be placed

against the patient's skin. United States Patent Application Serial No. 08/129,252 filed on September 29, 1993 describes the use of electroporation in conjunction with catheters in more detail and is incorporated by  
5 reference.

Referring to Figures 9 and 10, a catheter 20 that utilizes phonophoresis has a tubular ultrasonic transducer 112 that circumscribes catheter body 22 in the gap between distal occlusion balloon 30 and proximal  
10 occlusion balloon 34. Referring to Figure 10, leads 100 and 110 pass through delivery lumen 44 and have one end attached to ultrasonic transducer 112 and an opposite end attached to power supply 102. There is a slight gap between ultrasonic transducer 112 and catheter body 22  
15 so that fluid can pass from delivery ports 56 into the prostatic urethra 90. A catheter 20 of the present invention that utilizes phonophoresis is used in a fashion similar to that described above for electroporation. United States Patent Application  
20 Serial No. 07/937,464 on August 28, 1992 describes the use of phonophoresis in conjunction with catheters in more detail and is incorporated by reference.

Heating the prostatic tissue and the fluid as it is transported into the prostatic ducts and/or the  
25 prostatic tissue may also enhance efficiency of certain types of drugs, including oncolytics. Efficiency is improved by increasing tissue penetration and cellular uptake of the drug. Referring to Figure 11, a catheter 20 of the present invention that employs heating has a  
30 coil-wire resistor 114 that forms a heating element. Coil-wire resistor 114 circumscribes catheter body 22 and is located between distal occlusion balloon 30 and proximal occlusion balloon 34.

Leads 100 and 110 pass through delivery lumen 44  
35 and have a first end that is attached to coil-wire resistor 114 and a second end that is attached to power supply 102. A prostatic catheter 20 that utilizes

heating is used in a fashion similar to that described above for electroporation or phonophoresis. One skilled in the art will realize that an ultrasonic transducer can be used in place of a coil-wire resistor to provide  
5 thermal energy within the prostatic urethra.

While the invention has been described in conjunction with a specific embodiment thereof, it is evident that different alternatives, modifications, and variations will be apparent to those skilled in the art  
10 in view of the foregoing description. Accordingly, the invention is not limited to these embodiments or the use of elements having specific configurations and shapes as presented herein.

The invention that we claim is:

1. An apparatus for treating a prostate gland of a patient, the apparatus comprising:
  - 5 a) a catheter having a distal end and a proximal end;
  - b) means for delivering a fluid to the prostatic urethra;
  - c) means for positioning at least a portion  
10 of the means for delivering fluid within the prostatic urethra relative to the patient's bladder;
  - d) means for isolating the prostatic urethra from the membranous urethra and the  
15 urinary bladder, wherein most of the fluid is retained within the prostatic urethra; and
  - e) means for transporting the fluid into the prostatic ducts wherein substantially all  
20 of the prostatic ducts remain open during delivery.
2. The apparatus of claim 1 wherein the means for positioning comprises a positioning balloon operably  
25 connected to the catheter proximate the distal end, the positioning balloon being insertable into the bladder and inflatable within the bladder, wherein insertion into and inflation within the bladder enables the means for delivering fluid to be located within the prostatic  
30 urethra.
3. The apparatus of claim 2 wherein the positioning balloon has a diameter in the range of approximately 2 cm to approximately 4 cm when inflated.  
35
4. The apparatus of claim 2 wherein the catheter defines an inflation lumen extending from a position

proximate the proximal end to a position proximate the positioning balloon, and further wherein the positioning balloon is in fluid communication with the inflation lumen.

5

5. The apparatus of claim 1 wherein the means for isolating includes first and second occlusion balloons operably connected to the catheter, the first and second occlusion balloons being located on opposite sides of the prostatic urethra wherein at least a portion of the means for delivering fluid is within the prostatic urethra, thereby retaining substantially all of the fluid within the prostatic urethra for delivery to the prostatic ducts.

15

6. The apparatus of claim 5 wherein the proximal and distal occlusion balloons are separated by a distance of approximately 3 cm to approximately 6 cm.

20

7. The apparatus of claim 5 wherein the catheter comprises an inflation lumen extending from a position proximate the proximal end of the catheter, and further wherein the proximal occlusion balloon is in fluid communication with the inflation lumen and the distal occlusion balloon is in fluid communication with the inflation balloon.

25

8. The apparatus of claim 5 wherein the catheter defines a delivery lumen that extends from a position proximate the proximal end and the delivery lumen is in fluid communication with the prostatic urethra when the at least a portion of the means for delivering fluid is within the prostatic urethra, further wherein the means for delivering fluid comprises the delivery lumen.

35

9. The apparatus of claim 18 wherein the means for delivering fluid further comprises a syringe in

fluid communication with the delivery lumen.

10. The apparatus of claim 9 wherein the catheter has an outer surface and defines at least one aperture, each of the at least one apertures passing from the delivery lumen to the outer surface.

11. The apparatus of claim 10 wherein each of the at least one apertures has a diameter in the range of approximately 0.5 mm to approximately 2 mm.

12. The apparatus of claim 5 wherein the distance separating the proximal and distal occlusion balloons is adjustable.

13. The apparatus of claim 12 wherein the catheter comprises first and second parts wherein the first occlusion balloon is operably connected to the first part and the second occlusion balloon is operably connected to the second part, further wherein the first part is slidably connected to the second part so that the distance between the proximal and distal occlusion balloons is adjustable.

14. The apparatus of claim 13 wherein the first part defines a first inflation lumen extending from a position proximate the proximal end and the proximal occlusion balloon is in fluid communication with the first inflation lumen, and further wherein the second part defines a second inflation lumen extending from a position proximate the proximal end and the distal occlusion balloon is in fluid communication with the second inflation lumen.

15. The apparatus of claim 13 wherein the first and second parts cooperate to define a gap between the first and second parts, wherein the gap forms a delivery



lumen and the delivery lumen is in fluid communication with the prostatic urethra when the at least a portion of the means for delivering fluid is within the prostatic urethra, still further wherein the means for  
5 delivering fluid comprises the delivery lumen.

16. The apparatus of claim 15 wherein the means for delivering fluid further comprises a syringe in fluid communication with the delivery lumen.

10

17. The apparatus of claim 13 wherein the first part has an outer surface and the second part is hollow and has an inner surface, the first part being slidably inserted into the second part, further wherein the  
15 inside surface of the second part defines a groove, still further wherein the groove and the outer surface of the first part form a delivery lumen and the delivery lumen is in fluid communication with the prostatic urethra when the at least a portion of the means for  
20 delivering fluid is within the prostatic urethra, still further wherein the means for delivering fluid comprises the delivery lumen.

18. The apparatus of claim 15 wherein the means  
25 for delivering fluid further comprises a syringe in fluid communication with the delivery lumen.

19. The apparatus of claim 13 wherein the first part defines a delivery lumen that extends from a  
30 position proximate the proximal end and the delivery lumen is in fluid communication with the prostatic urethra when the at least a portion of the means for delivering fluid is within the prostatic urethra, further wherein the means for delivering fluid comprises  
35 the delivery lumen.

20. The apparatus of claim 13 wherein the second part defines a delivery lumen that extends from a position proximate the proximal end and the delivery lumen is in fluid communication with the prostatic urethra when the at least a portion of the means for delivering fluid is within the prostatic urethra, further wherein the means for delivering fluid comprises the delivery lumen.

21. The apparatus of claim 1 wherein the means for transporting comprises means for pressurizing the fluid.

22. The apparatus of claim 21 wherein the means for pressurizing comprises a syringe in fluid communication with the delivery lumen.

23. The apparatus of claim 21 wherein the means for transporting further comprises phonophoresis means for providing ultrasonic energy within the prostatic urethra.

24. The apparatus of claim 23 wherein the phonophoresis means comprises a transducer operably connected to the catheter and located between the proximal and distal occlusion balloons.

25. The apparatus of claim 21 wherein the means for transporting further comprises iontophoresis means for providing a voltage gradient across the prostate gland.

26. The apparatus of claim 25 wherein the iontophoresis means comprises an electrode operably connected to the catheter and located between the proximal and distal occlusion balloons.

27. The apparatus of claim 21 wherein the means for transporting further comprises means for heating the fluid in the prostatic urethra.

5        28. The apparatus of claim 27 wherein the means for heating further heats the prostatic tissue.

29. The apparatus of claim 27 wherein the means for heating comprises a resistive heating element  
10 operably connected to the catheter and located between the proximal and distal occlusion balloons.

30. The apparatus of claim 27 wherein the means for heating comprises an ultrasonic transducer operably  
15 connected to the catheter and located between the proximal and distal occlusion balloons.

31. The apparatus of claim 1 wherein the catheter defines a drainage lumen that extends from a position  
20 proximate the proximal end to a position proximate the distal end.

32. The apparatus of claim 1 wherein the means for positioning comprises an inflatable positioning balloon  
25 operably connected to the catheter proximate the distal end, the positioning balloon having a first portion that is insertable into the bladder and a second portion that is insertable into the neck of the bladder, wherein the positioning balloon is sized so that when inflated, the  
30 first portion is seated at junction between the bladder and the neck of the bladder and the second portion isolates the prostatic urethra from the neck of the bladder, thereby preventing substantially all of the fluid from passing into the bladder.

35

33. The apparatus of claim 32 wherein the means for isolating includes an occlusion balloon operably

connected to the catheter, wherein the occlusion balloon is located on the opposite side of the prostate gland from the positioning balloon when the catheter is in the drug delivery position, thereby isolating substantially all of the membranous urethra from substantially all of the fluid.

34. An apparatus for delivering a fluid to a prostate gland of a patient, the apparatus comprising:

- 10 a) a catheter having distal and proximal ends, a drainage lumen, at least one inflation lumen, and a delivery lumen ;
- 15 b) a positioning balloon operably connected to the distal end of the catheter, wherein the at least one inflation lumen is capable of passing inflation fluid to the interior of the positioning balloon;
- 20 c) a proximal occlusion balloon operably connected to the catheter wherein the at least one inflation lumen is capable of passing inflation fluid to the interior of the proximal occlusion balloon; and
- 25 d) a distal occlusion balloon situated between the positioning balloon and the proximal occlusion balloon and operably connected to the catheter wherein the at least one inflation lumen is capable of delivering inflation fluid to the interior of the distal occlusion balloon,
- 30 further wherein the proximal occlusion balloon is capable of isolating substantially all of the prostatic urethra from substantially all of the membranous urethra and the distal occlusion balloon is capable of
- 35 preventing most of the fluid from passing into the bladder, still further wherein

the delivery lumen is capable of passing fluid to the gap between the distal and proximal occlusion balloons.

- 5           35. An apparatus for delivering a fluid to a prostatic gland of a patient, the apparatus comprising:
- 10           a) a catheter having distal and proximal ends, a drainage lumen, at least one inflation lumen, and a delivery lumen;
  - b) a positioning balloon operably connected to the distal end of the catheter, wherein the at least one inflation lumen is capable of passing inflation fluid to the interior of the positioning balloon;
  - 15           c) a proximal occlusion balloon operably connected to the catheter wherein the at least one inflation lumen is capable of passing inflation fluid to the interior of the proximal occlusion balloon;
  - 20           d) a distal occlusion balloon situated between the positioning balloon and the proximal occlusion balloon and operably connected to the catheter so that the gap between the distal occlusion balloon and the proximal occlusion balloon is in the range between approximately 3 centimeters to approximately 6 centimeters, wherein the at least one inflation lumen is capable of delivering inflation fluid to the interior of the distal occlusion balloon, further wherein the proximal occlusion balloon is capable of isolating substantially all of the prostatic urethra from substantially all of the membranous urethra and the distal occlusion balloon is capable of preventing most of the fluid from passing
  - 25
  - 30
  - 35

into the bladder, still further wherein the delivery lumen is capable of passing the fluid to the gap between the distal and proximal occlusion balloons; and

- 5           e) a mechanism for injecting the fluid through the delivery lumen and for pressurizing the fluid within the prostatic urethra.

10   36. A method of delivering fluid to a prostate gland of a patient, the method comprising the steps of:

- 15           a) positioning a portion of a catheter within the prostatic urethra; the portion of the catheter within the prostatic urethra having a diameter less than the diameter of the prostatic urethra;
- b) isolating the prostatic urethra from the membranous urethra and the urinary bladder;
- 20           c) delivering fluid through the catheter to the membranous urethra, wherein most of the fluid is retained within the prostatic urethra; and
- 25           d) pressurizing the fluid in the prostatic urethra to transport the fluid into the prostate gland.

37. The method of claim 36 wherein the catheter has a proximal end, a distal end, and a positioning balloon operably connected to the distal end, further wherein the step of positioning the catheter comprises the steps of:

- 35           a) inserting the distal end of the catheter through the membranous urethra and through the prostatic urethra until the positioning balloon is located with the urinary bladder;

- b) inflating the positioning balloon; and
- c) applying retrograde tension to the catheter so that the positioning balloon becomes seated against the junction between the urinary bladder and the neck of the urinary bladder.

5

38. The method of claim 36 wherein the catheter further comprises first and second occlusion balloons, and  
10 further wherein the step of isolating comprises the steps of inflating the first and second occlusion balloons.

39. The method of claim 38 further comprising the step  
15 of adjusting the distance between the first and second occlusion balloons.






FIG. 3




FIG. 5





FIG. 4





FIG. 4B




FIG. 4A






FIG. 9





FIG. 10

## INTERNATIONAL SEARCH REPORT

 Internat. Application No  
 PCT/US 95/00082

 A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61M25/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 474 906 (TRAVENOL LABORATORIES LTD) 18 March 1992	1-11, 34, 35
Y	see column 1, line 40 - column 2, line 9; figures 1,2	12-31
Y,P	US,A,5 342 306 (DON MICHAEL) 30 August 1994 see abstract see column 1, line 33 - column 2, line 8; figures 1,2	12-22, 31
Y,P	WO,A,94 05361 (CORTRAK MEDICAL, INC.) 17 March 1994 see page 4, line 36 - page 6, line 23; claims 1,4-7	23-30
A	WO,A,87 07510 (FINA) 17 December 1987	

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "E" document member of the same patent family

Date of the actual completion of the international search

21 April 1995

Date of mailing of the international search report

28 04 95

 Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 spo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Michels, N

## INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 95/00082

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,88 03389 (HALLGREN ET AL.) 19 May 1988 -----	
A	US,A,5 002 558 (KLEIN ET AL.) 26 March 1991 -----	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/00082

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 36-39  
because they relate to subject matter not required to be searched by this Authority, namely:  
see Rule 39.1 (iv) PCT: Method for treatment of the human or animal body by therapy.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat. Application No.

PCT/US 95/00082

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-474906	18-03-92	AU-B- 625267 AU-A- 6211190 US-A- 4976692	02-07-92 12-03-92 11-12-90
US-A-5342306	30-08-94	NONE	
WO-A-9405361	17-03-94	US-A- 5286254 AU-B- 3321293 AU-B- 3321793 EP-A- 0611311 JP-T- 7500523 WO-A- 9405369 US-A- 5282785	15-02-94 29-03-94 29-03-94 24-08-94 19-01-95 17-03-94 01-02-94
WO-A-8707510	17-12-87	US-A- 4911163	27-03-90
WO-A-8803389	19-05-88	SE-B- 455368 AU-A- 8271387 EP-A- 0288539 JP-T- 1502484 SE-A- 8604822	11-07-88 01-06-88 02-11-88 31-08-89 12-05-88
US-A-5002558	26-03-91	NONE	